Overview

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

Status:
Completed

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with methotrexate.

Phase:

Phase 4

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Collaborator:

Pharma Consulting Group AB

Treatments:

Adalimumab
Methotrexate